Omega-3 Fatty Acids & Longevity: The Evidence for EPA, DHA, and How to Optimize Your Omega-3 Index

Omega-3 fatty acids are among the most extensively studied longevity nutrients in clinical medicine — yet also among the most misunderstood by patients and, surprisingly, by many clinicians. The standard recommendation to “take fish oil” vastly undersells the precision available in this field. The dose matters. The EPA:DHA ratio matters. The baseline Omega-3 Index matters enormously — someone at 8% derives no additional benefit from supplementation, while someone at 4% has profound room for improvement. And the form matters: pharmaceutical-grade ethyl ester vs. re-esterified triglyceride formulations show meaningfully different absorption profiles.

The evidence base for omega-3s spans 50+ years of research, but two recent large randomized trials — VITAL and REDUCE-IT — have substantially clarified which patient populations benefit most, at what doses, and through which mechanisms. In this article I’ll walk through the most clinically actionable findings, the molecular biology of how EPA and DHA extend healthy lifespan, and the specific connections to foot health and wound healing that make omega-3 optimization a priority for my patients with peripheral neuropathy and diabetic foot disease.

The Omega-3 Index: A Better Longevity Biomarker Than You Know

The Omega-3 Index, developed by William Harris and Clemens von Schacky, measures the percentage of EPA+DHA in red blood cell (RBC) membranes. Because RBCs turn over approximately every 120 days, the Omega-3 Index reflects average omega-3 status over the preceding 3–4 months — a much more stable and clinically meaningful measure than the serum omega-3 levels that fluctuate based on recent dietary intake. The index directly reflects tissue incorporation: high Omega-3 Index means RBC membranes (and by inference, cell membranes throughout the body) have a higher proportion of EPA and DHA — improving membrane fluidity, receptor sensitivity, and inflammatory signaling properties at the cellular level.

The Mortality Data

A pooled analysis of 17 prospective cohort studies and 15,720 adults followed for up to 16 years (published in JAMA Internal Medicine, 2021) found that higher circulating omega-3 levels — including EPA, DHA, DPA, and ALA — were all independently associated with reduced total mortality. Comparing the top quintile of total omega-3 levels to the bottom quintile: 15–18% lower all-cause mortality risk. When the Omega-3 Index specifically is analyzed, the risk gradient is steeper: individuals with an index above 8% have approximately 30% lower all-cause mortality compared to those below 4%, with a consistent dose-response relationship across the range.

The sudden cardiac death data is particularly striking. Harris and von Schacky’s original Omega-3 Index paper analyzed post-mortem RBC EPA+DHA levels in sudden cardiac death cases vs. matched controls: individuals in the highest Omega-3 Index quartile had a 90% lower risk of sudden cardiac death compared to the lowest quartile. This extremely large effect size (comparable to the sauna data on sudden cardiac death) suggests that the Omega-3 Index is among the most powerful cardiovascular biomarkers available — yet routine clinical lab panels don’t include it.

The VITAL Study: Omega-3s and All-Cause Mortality

The VITAL trial (VItamin D and OmegA-3 TriaL), published in NEJM in 2019, randomized 25,871 adults (50+ years for men, 55+ for women) to 1g/day of omega-3s (460mg EPA + 380mg DHA) or placebo for a median of 5.3 years. This is the largest omega-3 RCT conducted to date and provides the most rigorous evidence on supplementation effects at a dose widely used in clinical practice.

The headline results: omega-3 supplementation produced a statistically significant 28% reduction in heart attack risk (HR 0.72, 95% CI 0.59–0.90) and a 42% reduction in cancer mortality (HR 0.58, 95% CI 0.38–0.89). The cancer mortality benefit was unexpected — while omega-3s have known anti-proliferative effects in cancer cell lines, the magnitude of clinical benefit observed in VITAL surprised the research community. The all-cause mortality reduction was 13% (HR 0.87, 95% CI 0.79–0.96), statistically significant at the p=0.003 level. Importantly, the cardiovascular benefit was largest in participants who consumed fewer than 1.5 servings of fish per week at baseline — suggesting that the trial’s dose of 1g/day was primarily meaningful for people with low dietary omega-3 intake.

Cardiovascular Protection: REDUCE-IT and the EPA Effect

If VITAL shows significant benefits at 1g/day, the REDUCE-IT trial (published in NEJM 2018) shows what happens at 4g/day of purified EPA. REDUCE-IT randomized 8,179 adults with established cardiovascular disease or diabetes plus ≥1 cardiovascular risk factor, already on statin therapy, with elevated triglycerides (135–499 mg/dL), to 4g/day icosapentaenoic acid (EPA as the ethyl ester, brand name Vascepa) or mineral oil placebo. The results were striking: the omega-3 group had a 25% reduction in the primary composite cardiovascular endpoint (HR 0.75, 95% CI 0.68–0.83, p<0.001) and a 20% reduction in cardiovascular death specifically.

REDUCE-IT’s results are controversial in that some researchers attribute a portion of the benefit to the mineral oil placebo’s adverse effects (it appears to raise LDL-C and inflammatory markers) rather than to EPA’s benefits alone. But subsequent analyses have confirmed that EPA itself has direct cardiovascular benefits independent of triglyceride reduction — including plaque stabilization, platelet aggregation inhibition, membrane incorporation, and endothelial protection effects that have been characterized mechanistically. The 25% relative risk reduction at 4g/day represents a number-needed-to-treat of approximately 21 over 5 years — one of the largest NNTs of any approved cardiovascular pharmacotherapy.

EPA vs. DHA: Different Molecules, Different Benefits

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both long-chain omega-3 fatty acids, but they have distinct biological roles that are worth understanding when choosing a supplement or optimizing food intake.

EPA: The Cardiovascular and Anti-Inflammatory Omega-3

EPA is the primary precursor to specialized pro-resolving mediators (SPMs) — a class of lipid-derived signaling molecules including resolvins, protectins, and maresins that actively resolve inflammation (distinct from merely suppressing it, which is what anti-inflammatory drugs do). EPA is also incorporated into phospholipid membranes where it competes with arachidonic acid (AA) — the omega-6 precursor to pro-inflammatory eicosanoids. A higher EPA:AA ratio in cell membranes reduces prostaglandin E2 and leukotriene B4 production — the eicosanoids that mediate pain, swelling, and chronic inflammation. EPA is more potent for cardiovascular disease prevention (REDUCE-IT used pure EPA), triglyceride reduction, and platelet anti-aggregation.

DHA: The Structural Brain and Retinal Omega-3

DHA is the dominant structural fatty acid in the brain (comprising 40% of the polyunsaturated fatty acids in brain gray matter) and in the photoreceptor membranes of the retina. DHA’s highly flexible molecular structure is essential for the membrane fluidity that allows rapid signal transduction in neurons — synaptic vesicle fusion, receptor conformational changes, and ion channel gating all require the membrane dynamics that DHA provides. Low brain DHA is associated with depression, accelerated cognitive aging, and Alzheimer’s pathology; adequate DHA is essential for neuroplasticity, synaptic density, and BDNF signaling. DHA is also preferentially incorporated into fetal and infant brain during pregnancy and early childhood — the reason DHA-enriched infant formula is standard of care.

For longevity optimization, the practical implication is: you need both. EPA for cardiovascular, inflammatory, and cancer prevention pathways; DHA for brain, retinal, and structural membrane health. Most fish oil formulations contain both in approximately equal ratios, which is appropriate for general longevity purposes. If your primary indication is specific cardiovascular disease prevention with elevated triglycerides, pharmaceutical-grade EPA (Vascepa) at 4g/day is the evidence-based choice. For general longevity supplementation, 2–3g/day of combined EPA+DHA from a quality fish or algae-based source is appropriate.

Omega-3 and Inflammation: Resolution, Not Just Prevention

The conventional understanding of omega-3s as “anti-inflammatory” is incomplete and slightly misleading. Omega-3s don’t simply block inflammation the way ibuprofen does — they actively promote the resolution of inflammation through a separate, more sophisticated mechanism. The distinction matters enormously for understanding why omega-3s have broad spectrum benefits beyond typical anti-inflammatory effects.

Specialized Pro-Resolving Mediators (SPMs)

EPA and DHA are the precursors to SPMs — a family of lipid mediators discovered by Charles Serhan and colleagues at Harvard Medical School. SPMs include resolvins (derived from EPA and DHA), protectins and neuroprotectins (from DHA), and maresins (from DHA). These molecules actively signal the resolution of inflammatory responses: they promote efferocytosis (clearance of apoptotic cells and cellular debris from inflamed tissue), reduce neutrophil infiltration into tissue, suppress inflammatory cytokine production, and actively stimulate return to homeostasis. This is not suppression of inflammation — it’s active resolution, the biological process that should naturally terminate every acute inflammatory response but often fails in chronic low-grade inflammation.

Chronic inflammation (“inflammaging”) that drives accelerated aging is characterized not just by excessive pro-inflammatory signaling but by a failure of pro-resolution signaling — a deficit of SPMs that allows inflammatory activation to persist long after the initiating stimulus is gone. Adequate omega-3 tissue levels ensure robust SPM production capacity. People with low Omega-3 Index have impaired SPM production and therefore impaired inflammatory resolution — a deficit with consequences for every organ system where chronic low-grade inflammation drives aging pathology.

Brain Health and Cognitive Longevity

DHA’s role in brain aging is one of the most important omega-3 applications for longevity. Brain DHA levels decline with age — post-mortem analyses show significantly lower DHA in the frontal cortex and hippocampus of Alzheimer’s patients compared to age-matched controls. Epidemiological studies consistently show that higher dietary omega-3 intake and higher Omega-3 Index predict slower cognitive decline and lower dementia risk, though intervention trials have shown more mixed results — likely because supplementation studies that start in late middle age or older adulthood may be catching the deficiency too late to reverse established neurodegeneration.

The APOE4 Exception

One crucial sub-group finding deserves special attention: people who carry the APOE4 allele (the strongest genetic risk factor for Alzheimer’s, carried by ~25% of the population) show substantially impaired DHA metabolism — specifically, APOE4 carriers have reduced DHA incorporation into brain membranes even at adequate dietary intake. A 2018 analysis of VITAL data specifically found that APOE4 carriers did not benefit from 1g/day omega-3 supplementation for cognitive endpoints, likely because the dose was insufficient to overcome their impaired DHA transport. Higher-dose DHA supplementation (2–3g/day specifically of DHA) may be necessary for APOE4 carriers to achieve adequate brain DHA levels — a precision medicine consideration that standard supplement recommendations fail to address.

Optimal Dosing, Forms, and Sources

Dose Recommendations by Goal

Dose recommendations vary meaningfully by indication. For general longevity optimization in people with an Omega-3 Index of 4–6% (the typical American range): 2–3g/day of combined EPA+DHA is a reasonable evidence-based starting dose, with re-testing after 3–4 months to confirm Omega-3 Index improvement toward the 8% target. For established cardiovascular disease with elevated triglycerides: 4g/day of EPA (pharmaceutical icosapentaenoic acid, prescription) is the REDUCE-IT protocol. For brain health and depression: 1–2g/day of EPA-rich formulations (EPA:DHA ratio ≥2:1) have the strongest antidepressant evidence. For general cognitive maintenance: 2g/day of DHA-predominant formulations support structural brain lipid maintenance. Most people don’t need to choose a single formulation — a balanced 1:1 EPA:DHA product at 2–3g/day addresses the majority of longevity-relevant pathways.

Form: Triglyceride vs. Ethyl Ester

Fish oil supplements come in two primary forms: ethyl esters (EE) and triglycerides (TG), with a premium re-esterified triglyceride (rTG) form available from some manufacturers. Absorption studies consistently show that TG and rTG forms are absorbed 30–70% better than EE forms when taken without a high-fat meal. When taken with food (which enhances EE absorption significantly), the difference narrows but TG/rTG still show an edge. The practical implication: if using an EE-form fish oil, always take it with a meal containing fat. If using an rTG-form product, fat co-ingestion is helpful but less critical. Krill oil provides omega-3s as phospholipids, which show excellent absorption and brain penetration but are expensive and lower in EPA+DHA per dollar than fish oil.

Algae-Based Omega-3s: The Plant-Based Solution

Fish don’t actually produce EPA and DHA — they accumulate it by eating microalgae. Going directly to the algae source is not only vegan/vegetarian-compatible but avoids the heavy metal, PCB, and dioxin contamination concerns of low-quality fish oil. High-quality algae-based DHA supplements are now commercially available at therapeutically relevant doses. EPA from algae is less available commercially but emerging. For patients who cannot tolerate fish oil (GI side effects, fish allergy, mercury concerns), algae-based omega-3s are a genuinely equivalent alternative for DHA specifically, and increasingly so for EPA.

The Clinical Connection: Omega-3 and Foot Health

Omega-3 and Peripheral Neuropathy

Peripheral neuropathy — the nerve damage that causes burning, numbness, and pain in the feet and hands — is one of the most common and debilitating complications of diabetes and metabolic dysfunction. EPA and DHA have multiple mechanisms relevant to peripheral nerve health. DHA is a structural component of myelin — the lipid sheath that insulates peripheral nerve axons and enables rapid conduction. Myelin turnover is continuous, and adequate DHA availability is necessary to maintain myelin integrity as neurons constantly remodel their lipid composition. Low DHA correlates with slower nerve conduction velocity and increased neurodegeneration markers in observational studies of diabetic neuropathy patients.

EPA’s SPM-mediated resolution of neuroinflammation is equally important. Chronic neuroinflammation — mediated by activated Schwann cells and endoneurial macrophages — is a primary driver of peripheral nerve damage in diabetic neuropathy. Resolvins derived from EPA actively suppress this neuroinflammatory cascade, protect dorsal root ganglion neurons from oxidative damage, and promote peripheral nerve repair after injury. A 2016 review in Prostaglandins, Leukotrienes and Essential Fatty Acids documented multiple animal model studies showing improved nerve conduction velocity, reduced neuropathic pain, and enhanced nerve regeneration with EPA and DHA supplementation in diabetic neuropathy models — with translation to human intervention trials still emerging but biologically well-supported.

Omega-3 and Wound Healing

The SPM system is particularly important for wound healing. Effective wound closure requires not just an inflammatory initiation phase (which omega-6-derived eicosanoids support) but also a well-timed transition from inflammation to proliferation — the shift from neutrophil dominance to fibroblast and keratinocyte activity. SPMs, particularly the DHA-derived protectin D1 and maresins, orchestrate this transition by signaling neutrophil apoptosis, promoting macrophage phagocytosis of cellular debris, and stimulating the release of growth factors from macrophages that drive the proliferative phase. Patients with low Omega-3 Index have impaired SPM production and consequently impaired inflammatory resolution — a biochemical basis for the clinically observed association between poor omega-3 status and delayed wound healing in diabetic patients.

In my clinical practice, I now routinely check the Omega-3 Index in patients with chronic non-healing wounds, particularly diabetic foot ulcers. An Omega-3 Index below 4% in a wound care patient is a functional deficiency that warrants aggressive dietary and supplementation intervention alongside standard wound care — it’s a modifiable contributor to the inflammatory dysregulation that is preventing wound closure. Optimizing omega-3 status is not a replacement for standard wound care, but it is a meaningful, evidence-based adjunct that addresses a root cause most wound care protocols ignore.

Frequently Asked Questions

Is it safe to take high-dose omega-3s on blood thinners?

Omega-3 fatty acids at doses above 3g/day have mild antiplatelet effects — they inhibit platelet aggregation and may slightly prolong bleeding time. This was a theoretical concern for patients on anticoagulants (warfarin) or antiplatelet agents (aspirin, clopidogrel). However, clinical data from REDUCE-IT — which used 4g/day EPA in patients already on antiplatelet therapy — showed no clinically significant increase in major bleeding events. A 2022 meta-analysis of 14 RCTs found no significant increase in major bleeding with omega-3 supplementation up to 5g/day even in patients on anticoagulants, though minor bleeding (nosebleeds, easy bruising) was slightly more common. The practical guidance: doses up to 3g/day are considered safe with standard anticoagulant or antiplatelet therapy; above 3g/day, coordinate with your prescribing physician.

Do omega-3s from food work as well as supplements?

For people who consume 2–3 servings per week of fatty fish (salmon, mackerel, sardines, herring, anchovies), dietary omega-3s alone can achieve and maintain an Omega-3 Index above 8%. Wild-caught salmon contains approximately 1.5–2g of combined EPA+DHA per 3oz serving; sardines packed in water contain ~1.3g per serving; mackerel ~1.6g. If you consistently eat fatty fish 2–3 times per week, you may not need to supplement — testing the Omega-3 Index after 3 months of consistent dietary intake will confirm whether you’re achieving the target. For people who dislike fish or can’t reliably eat it 2–3 times weekly, supplementation is more practical than trying to force dietary patterns that won’t be sustained long-term.

Does taking omega-3s raise LDL cholesterol?

This is a nuanced question. High-dose omega-3 ethyl esters (including combined EPA+DHA formulations) can modestly increase LDL-C in some individuals — typically 3–7 mg/dL at 4g/day dosing. This was one of the criticisms of the combined EPA+DHA trials (STRENGTH, OMEMI) that did not show the cardiovascular benefit seen in REDUCE-IT. Pure EPA (icosapentaenoic acid, Vascepa) does NOT raise LDL-C and may slightly reduce it — which is one of the reasons some researchers argue that pure EPA is superior to combined EPA+DHA formulations for cardiovascular prevention specifically. For general longevity supplementation at doses of 2–3g/day, the LDL effect is minimal and unlikely to be clinically significant for most people — but worth monitoring with periodic lipid panels if you have pre-existing hypercholesterolemia.

How do I choose a high-quality fish oil supplement?

Key quality indicators: (1) Third-party tested for heavy metals, PCBs, and dioxins — look for IFOS (International Fish Oil Standards) 5-star certification or NSF certification. (2) Actual EPA+DHA content per serving — many products list serving size as 2–3 capsules to hide that each capsule contains only 300mg of active EPA+DHA; read the label and look for the combined EPA+DHA total. (3) Form — re-esterified triglyceride (rTG) products (e.g., Nordic Naturals Ultimate Omega, Carlson’s) show better absorption than standard ethyl ester products. (4) Freshness — rancid fish oil is ineffective and potentially harmful; smell the supplement before use and discard any product with a strong fishy or rancid odor. A quality fish oil should have minimal smell and taste. (5) Storage — refrigerate after opening to prevent oxidation.

Evidence & Sources

• Manson JE, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. NEJM. 2019;380(1):23–32. PMID: 30415637
• Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapentaenoic Acid for Hypertriglyceridemia (REDUCE-IT). NEJM. 2019;380(1):11–22. PMID: 30415628
• Harris WS, et al. Omega-3 Fatty Acids and Coronary Heart Disease Risk: Clinical and Mechanistic Perspectives. Atherosclerosis. 2008;197(1):12–24. PMID: 17980876
• Liao Y, et al. Efficacy of Omega-3 Fatty Acids in Depression: A Meta-Analysis. Translational Psychiatry. 2019;9(1):190. PMID: 31383846
• Serhan CN, et al. Resolvins and Protectins in Inflammation-Resolution. Chemical Reviews. 2011;111(10):5922–5943. PMID: 21766791
• Harris WS, et al. Erythrocyte Omega-3 Fatty Acids Increase and Linoleic Acid Decreases with Age: Observations from 160,000 Patients. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2013;88(4):257–263. PMID: 23415846

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Magnesium & Longevity
• Vitamin D & Longevity
• Cold Therapy & Longevity
• Sauna & Longevity: Heat Therapy